Understanding Pneumonia: Strains, Diagnosis, and Treatment

Pneumonia is a lung infection caused by bacteria, viruses, or fungi, and which organism is responsible changes nearly everything about how it is diagnosed, how dangerous it is, and how it should be treated. It remains one of the leading infectious causes of death worldwide, killing an estimated 1.3 million children alone in a single year and sending millions of adults to the hospital annually. Yet pneumonia is actually an unusual outcome of breathing in microbes; most of the time, the lungs’ own defenses clear infections before they take hold.¹ Understanding which organisms cause pneumonia, how they are identified, and how clinicians choose treatments can help you make sense of a diagnosis that many people experience as confusing and frightening.

Where You Catch It Shapes What You’re Fighting

Clinicians divide pneumonia into categories based on where the infection was acquired, because the setting strongly predicts which pathogens are involved and how severe the illness is likely to be. Community-acquired pneumonia (CAP) refers to infections picked up in everyday life. Healthcare-associated pneumonia (HCAP) strikes people who have had recent contact with medical facilities, such as nursing home residents or patients receiving dialysis. Hospital-acquired pneumonia (HAP) develops during a hospital stay.

These distinctions are not academic. In one study of culture-positive pneumonia cases, patients with HCAP had a hospital mortality rate of roughly 25%, compared with about 9% for CAP patients. HCAP patients were also more than twice as likely to receive the wrong initial antibiotics, which was itself an independent risk factor for dying in the hospital.² The pathogens explain much of this gap. In CAP and HCAP, Streptococcus pneumoniae tends to be the most common gram-positive culprit, while gram-negative bacteria like Pseudomonas aeruginosa appear more often in healthcare settings. HAP is dominated by tougher organisms, including methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Acinetobacter baumannii, and carries a 30-day mortality rate that can exceed 30%.³

Streptococcus Pneumoniae and How It Evades Your Defenses

Streptococcus pneumoniae, often just called the pneumococcus, is the single most common bacterial cause of community-acquired pneumonia worldwide. It is also one of the leading causes of vaccine-preventable severe pneumonia in children under five.⁴ What makes this bacterium so successful is its polysaccharide capsule, a sugar-based outer shell that comes in over 90 distinct types, or serotypes. This capsule is more than structural; it actively interferes with the immune system’s ability to kill the bacterium.

Research shows that the capsule blocks the body’s complement system, a set of blood proteins that normally tag bacteria for destruction, from depositing key markers on the bacterial surface. It also masks the antigens underneath the capsule so that antibodies and other immune molecules have trouble recognizing and binding to the bacterium. Even when immune cells do encounter encapsulated pneumococci, phagocytosis (the process where white blood cells engulf and digest invaders) is substantially reduced compared to unencapsulated strains.⁵ This multi-layered immune evasion is one reason pneumococcal pneumonia can progress so rapidly in vulnerable people.

Adding to the challenge, pneumococcal resistance to common antibiotics, including beta-lactams and macrolides, has spread globally. This complicates the empirical treatment approach that clinicians rely on when they need to start antibiotics before lab results come back.⁶

Atypical Bacteria and Why They Are Hard to Tell Apart

Not all bacterial pneumonias look or behave the same. A group of pathogens loosely called “atypical” bacteria includes Mycoplasma pneumoniae, Legionella pneumophila, and Chlamydophila pneumoniae. They are called atypical partly because they do not respond to the standard penicillin-class antibiotics and partly because their clinical presentations can differ from classic pneumococcal pneumonia.

In practice, however, telling these infections apart at the bedside is harder than textbooks suggest. A comparison of community-acquired cases found that Legionnaires’ disease patients were more likely to present with confusion, blood in the urine, and liver enzyme abnormalities than those with pneumococcal or mycoplasma pneumonia.⁷ Mycoplasma patients tended to be younger and more likely to have upper respiratory symptoms like sore throat and runny nose. But a separate study of over 200 cases concluded that no truly unique clinical features reliably distinguished any one group from the others; the overlap in symptoms, lab values, and chest imaging was substantial.⁸ This is why current treatment guidelines generally recommend covering atypical organisms empirically, rather than trying to guess the pathogen from the clinical picture alone.

Viral and Fungal Pneumonia

Bacteria are not the only cause. Respiratory viruses, including influenza, respiratory syncytial virus (RSV), and SARS-CoV-2, can cause pneumonia directly or set the stage for a secondary bacterial infection on top of the viral one. The interaction between viruses and bacteria in the lungs is complex: viral infection damages the airway lining, impairs immune cell function, and changes the local microbial environment, all of which make it easier for bacteria to gain a foothold.⁹ This is why bacterial pneumonia following a bout of flu has been a well-recognized killer for over a century.

Fungal pneumonia occupies a different niche. It is uncommon in people with healthy immune systems but can be devastating for those with blood cancers or recipients of stem cell transplants. In that population, fungal infections account for roughly a quarter to half of all pneumonias, with Aspergillus species being the most frequent culprit.¹⁰ Other fungal causes include Mucor, Fusarium, and Candida species. The high mortality from fungal pneumonia in these patients stems from both the severity of the infection and the profound immune dysfunction caused by their underlying disease or its treatment.¹¹

How Pneumonia Is Diagnosed

Diagnosing pneumonia involves more than listening to someone’s lungs with a stethoscope, though that remains a first step. Clinicians typically combine clinical assessment, imaging, and sometimes laboratory testing to confirm the diagnosis and identify the cause.

Imaging Beyond the Standard Chest X-Ray

A chest X-ray has long been the go-to imaging tool, but it misses a meaningful number of cases. In one study comparing both methods against CT scan as the gold standard, lung ultrasound detected pneumonia in about 91% of confirmed cases, while chest X-ray caught only about 73%.¹² A meta-analysis across multiple adult studies confirmed the pattern, finding that lung ultrasound had a pooled sensitivity of 88% and specificity of 86% for pneumonia diagnosis.¹³ In children, the performance was even stronger, with sensitivity reaching 94% and specificity 96%.¹⁴ Lung ultrasound is portable, involves no radiation, and can be performed at the bedside, which makes it especially valuable in emergency departments, pediatric units, and resource-limited settings.

Identifying the Pathogen

Knowing that someone has pneumonia is only half the battle. Figuring out which organism is responsible guides treatment. Traditional cultures, where a sample of sputum or blood is grown in the lab, remain important but can take days to return results. Multiplex PCR testing has changed this landscape by identifying bacterial and fungal pathogens within hours rather than days, enabling faster switches from broad-spectrum to targeted antibiotics.¹⁵ This speed matters: recall that receiving the wrong initial antibiotic is independently associated with higher mortality in pneumonia patients.

Severity Scoring

Once pneumonia is confirmed, clinicians use scoring tools to decide whether a patient can be treated at home or needs hospital admission, and whether they require intensive care. Two widely used tools are the Pneumonia Severity Index (PSI) and the CURB-65 score. A meta-analysis comparing the two found that both performed well at identifying high-risk patients, but CURB-65 was slightly better at predicting early mortality and the need for ICU admission, with a sensitivity of about 97% and specificity of 89% for predicting intensive care needs.¹⁶ CURB-65 has the added advantage of being simpler: it uses five easily assessed variables (confusion, blood urea, respiratory rate, blood pressure, and age 65 or older) and can be calculated in seconds.

Antibiotic Treatment Guidelines

Treatment for bacterial pneumonia depends heavily on whether you are being treated as an outpatient or in a hospital, and on whether you have underlying health conditions. The joint guidelines from the American Thoracic Society and the Infectious Diseases Society of America lay out a tiered approach.

For otherwise healthy outpatients with no chronic diseases and no risk factors for drug-resistant bacteria, the first-line recommendation is amoxicillin. Alternatives include doxycycline or a macrolide antibiotic like azithromycin, though macrolides are only recommended in areas where pneumococcal resistance to them is below 25%.¹⁷

For outpatients with chronic conditions like heart disease, lung disease, diabetes, or liver or kidney problems, guidelines recommend combination therapy: a beta-lactam antibiotic paired with a macrolide or doxycycline. A respiratory fluoroquinolone like levofloxacin or moxifloxacin is an alternative for patients who cannot tolerate the combination.¹⁷

For hospitalized patients without risk factors for MRSA or Pseudomonas, the standard regimen is either a beta-lactam (such as ceftriaxone) combined with a macrolide, or monotherapy with a respiratory fluoroquinolone. Both approaches carry strong evidence behind them.¹⁸ When risk factors for resistant organisms are present, such as recent hospitalization, prior antibiotic use, or structural lung disease, clinicians broaden coverage accordingly.

The Corticosteroid Question

You may have heard that steroids can help with severe pneumonia by tamping down the inflammatory response that damages the lungs. The reality is more nuanced, and the answer depends on whether the pneumonia is bacterial or viral.

For severe bacterial community-acquired pneumonia, there is growing evidence that a short course of corticosteroids may reduce mortality and length of stay, and some recent guidelines now conditionally recommend them in specific severe cases. But for viral pneumonia, particularly influenza-related cases, the evidence is far less encouraging. A meta-analysis of studies on corticosteroid use in influenza pneumonia and acute respiratory distress syndrome found no clear benefit and concluded that current data do not support routine use in that setting.¹⁹ A separate study focused specifically on viral community-acquired pneumonia found no difference in 30-day mortality between patients who received corticosteroids and those who did not.²⁰ The takeaway: corticosteroids are not a one-size-fits-all tool for pneumonia, and their use requires careful judgment about the underlying cause.

Oxygen Support for Severe Cases

When pneumonia causes severe drops in blood oxygen, patients need respiratory support. For those not yet requiring a ventilator, two options have gained attention: high-flow nasal oxygen (HFNO) and continuous positive airway pressure (CPAP). Both deliver oxygen more effectively than a standard mask and can sometimes help patients avoid intubation. Early data comparing the two in severe community-acquired pneumonia found no significant difference in ventilator-free days or mortality between them.²¹ Both approaches appear promising as tools to bridge the gap between standard oxygen therapy and full mechanical ventilation, though their exact roles are still being defined by ongoing research.²²

Pneumococcal Vaccines and Prevention

Vaccination remains the most effective way to prevent the most common bacterial pneumonias. Pneumococcal vaccines target the polysaccharide capsule that makes S. pneumoniae so dangerous. Two main types have been in use for years: conjugate vaccines (like PCV13, which covers 13 serotypes) and the polysaccharide vaccine PPSV23, which covers 23. A systematic review and meta-analysis confirmed that both PCV13 and PPSV23 protect adults against invasive pneumococcal disease and vaccine-type pneumococcal pneumonia.²³

The field is moving toward broader-coverage conjugate vaccines. A cost-effectiveness analysis estimated that replacing PCV13 with the newer PCV20 in infants could prevent over 2.5 million pneumonia cases and roughly 19,000 deaths across all age groups over a ten-year period in the United States, with a large share of those benefits flowing to unvaccinated adults through indirect (herd) effects.²⁴ An even newer 21-valent conjugate vaccine (PCV21) is being evaluated for adults, and early cost-effectiveness modeling suggests it could be cost-saving when used in risk-based strategies targeting higher-risk populations.²⁵

Cardiovascular Risk After Recovery

One of the more surprising findings in pneumonia research over the past decade is that surviving a bout of pneumonia does not mean returning to your previous baseline of health. Pneumonia survivors face a measurably higher risk of cardiovascular events, including heart attacks, heart failure, and strokes, that persists for years.

A large cohort study found that the risk of cardiovascular disease was highest in the first 30 days after hospitalization for pneumonia, with a hazard roughly four times that of matched controls. The elevated risk diminished over time but remained statistically significant even into the seventh year of follow-up.²⁶ A more recent register-based study confirmed this time-dependent pattern: hospitalized pneumonia patients had about four to seven additional cardiovascular events per 1,000 person-years in the first three months compared with healthy controls, and the excess risk remained significant for up to six years. Outpatients showed a similar but smaller and shorter-lasting elevation in risk.²⁷

The proposed mechanism is that the intense inflammatory response during pneumonia accelerates atherosclerotic vascular disease, the buildup of plaques in arteries, which can then lead to heart attacks and strokes down the road.²⁸ This has practical implications: if you or a family member recovers from pneumonia, it is worth discussing cardiovascular risk monitoring with a physician, especially in the first year or two after the infection.

Pneumonia in Young Children

Pneumonia is the single leading infectious cause of death in children under five globally. Estimates put the annual toll at roughly 700,000 to 740,000 deaths, with over 80% occurring in the first two years of life.⁴ The dominant organisms are the same pneumococcus discussed throughout this article and respiratory syncytial virus (RSV). Malnutrition, lack of access to vaccines, indoor air pollution from cooking fires, and limited healthcare infrastructure concentrate the burden in low- and middle-income countries.

Diagnosis in young children can be trickier than in adults. Children may not produce sputum, and younger infants often present with nonspecific symptoms like poor feeding and irritability. Lung ultrasound has proven particularly useful here, given its high sensitivity and the advantage of avoiding radiation exposure. The management principles are similar to those in adults, with amoxicillin as a first-line antibiotic for outpatient bacterial pneumonia and broader-spectrum agents reserved for hospitalized or severely ill children. Expanding access to pneumococcal conjugate vaccines and future RSV vaccines stands to prevent hundreds of thousands of these deaths.

The Lung Microbiome and Susceptibility

An emerging area of research is the role of the lung’s resident microbial community in determining who gets pneumonia and who fights it off. The lungs are not sterile; they harbor a community of microbes that interact with each other and with the immune system in ways that influence susceptibility to infection. These microbe-host and microbe-microbe interactions affect immune tone in the lower airways, essentially priming or dampening the local immune response depending on the composition of the community.²⁹ Disruptions to this microbial balance, whether from antibiotics, smoking, chronic illness, or mechanical ventilation, may create openings for pathogenic bacteria to gain dominance. This line of investigation is still in its early stages, but it may eventually help explain why some people develop pneumonia from organisms that their neighbors breathe in and shrug off without a second thought.